Form 4: Stoke Therapeutics COO Huw Nash Executes Stock Option and Sells Shares

Huw M. Nash, COO & CBO of Stoke Therapeutics, exercised stock options and sold a portion of the acquired shares on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Huw M. Nash, the COO & CBO of Stoke Therapeutics, exercised stock options to acquire 50,000 shares of common stock at a price of $0.40 per share.
• Simultaneously, Nash sold 400 shares of common stock at $13.2247 and another 400 shares at $13.61.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 29, 2023.
• Following these transactions, Nash directly owns 60,929 shares of common stock.
• Nash also holds options for 96,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions by an executive. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on any specific positive or negative information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to assess management's confidence in the company's prospects. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The use of a Rule 10b5-1 trading plan is a common strategy among executives to avoid accusations of insider trading, aligning with best practices in corporate governance.
• Comparable companies like BioMarin Pharmaceutical and Sarepta Therapeutics also have executives who utilize 10b5-1 plans for stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• The disclosure provides transparency to stakeholders regarding executive compensation and stock ownership.

Key Dates